ERBB2 and breast neoplasm: In our study the TP53 c.847C>T variant was associated with the NBN c.511A>G mutation, which is classified as VUS and HER2 +, corresponding to the immunohistochemical phenotype of breast tumors with pathogenic TP53 mutations.